Semaglutide vs. Tirzepatide: The Science Behind the Most Powerful Weight Loss Medications of the Decade
Semaglutide vs. Tirzepatide: What the Head-to-Head Trial Actually Showed
Short answer:Tirzepatide produces more weight loss than semaglutide. This is no longer an inference. In May 2025, theNew England Journal of Medicinepublished SURMOUNT-5, the first trial to compare the two drugs directly. Over 72 weeks in 751 adults with obesity and without diabetes, tirzepatide reduced body weight by an average of 20.2% versus 13.7% for semaglutide. Waist circumference fell 18.4 cm versus 13.0 cm. Both differences were statistically significant (P<0.001).
That said, more weight loss does not automatically make tirzepatide the right medication for a given patient. Cost, insurance coverage, tolerability, and individual response all matter, and a meaningful number of people do very well on semaglutide.
What is the difference between semaglutide and tirzepatide?
Both are once-weekly injectable medications that mimic gut hormones controlling appetite, blood sugar, and digestion. The difference is how many hormone pathways each one activates.
Semaglutide is a GLP-1 receptor agonist.It activates a single pathway, glucagon-like peptide-1, which signals fullness and slows how quickly the stomach empties.
Tirzepatide is a dual GIP/GLP-1 receptor agonist.It activates the GLP-1 pathway plus a second one, glucose-dependent insulinotropic polypeptide. The SURMOUNT-5 authors noted that GIP receptors are expressed in brain regions that only partly overlap with GLP-1 receptor regions, and hypothesized that this broader coverage explains the larger weight reduction seen with dual agonism.
Which medication causes more weight loss?
Tirzepatide, by a clear margin.
Before May 2025, the honest answer was "probably tirzepatide, but we're comparing across studies." Semaglutide's roughly 15% figure came from the STEP 1 trial and tirzepatide's roughly 21% came from SURMOUNT-1 — different participants, different study designs, so the comparison was suggestive rather than definitive.
SURMOUNT-5 settled it. It was a randomized, open-label, phase 3b trial that assigned 751 adults with obesity, but without type 2 diabetes, to the maximum tolerated dose of either drug for 72 weeks.
SURMOUNT-5 head-to-head results at 72 weeksOutcomeTirzepatideSemaglutideMean body weight reduction20.2%13.7%Mean weight lost22.8 kg (~50 lbs)15.0 kg (~33 lbs)Waist circumference change−18.4 cm−13.0 cmDiscontinued due to GI side effects2.7%5.6%Serious adverse events4.8%3.5%
Tirzepatide patients were also more likely to hit every weight-loss threshold measured, from at least 10% through at least 25% of body weight.
One finding from this trial deserves more attention than it gets.Weight loss was approximately 6% lower in men than in women in both treatment groups.SURMOUNT-5 enrolled a higher share of men (35%) than most obesity trials, and the investigators believe this is part of why overall results came in slightly below earlier studies. If you are a man evaluating these medications, the widely quoted averages likely overstate what you should expect.
Which one has worse side effects?
Counterintuitively, tirzepatide was better tolerated in the head-to-head trial despite producing more weight loss.
Gastrointestinal side effects severe enough to stop treatment occurred in 5.6% of semaglutide patients versus 2.7% of tirzepatide patients. Most adverse events in both groups were mild to moderate and clustered during dose escalation, which is the period when careful titration matters most.
Serious adverse events were uncommon and similar between groups: 4.8% with tirzepatide and 3.5% with semaglutide. Across the full trial there were no confirmed major cardiovascular events, no deaths, no cases of medullary thyroid cancer, and no cases of pancreatic cancer. One confirmed case of pancreatitis occurred in the semaglutide group.
Common side effects for both drugs include nausea, vomiting, diarrhea, constipation, and reflux. Both carry a boxed warning regarding thyroid C-cell tumors observed in rodents, and neither is appropriate for anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2.
Does more weight loss mean tirzepatide is the better choice?
Not necessarily, and this is where population averages stop being useful.
A 20.2% average means some participants lost far more and some lost considerably less. Trial averages describe groups. They do not predict what any individual will do. Several factors matter more in practice than which drug has the higher headline number:
Insurance and cost.Coverage differs substantially between the two drugs and shifts frequently. For many patients this is the deciding factor.
Tolerability.Some patients handle one molecule comfortably and struggle with the other. This is not predictable in advance.
Comorbidities.Semaglutide has the larger cardiovascular outcomes evidence base at present, which can matter for a patient with established cardiovascular disease.
Titration discipline. In both SURMOUNT-5 arms, maximum benefit appeared at the highest tolerated doses after roughly 1.4 years. Patients pushed too fast tend to quit during escalation and never reach an effective dose.
Muscle preservation.Rapid weight loss without adequate protein intake and resistance training costs lean mass. This is a monitoring problem, not a medication problem, and it applies equally to both drugs.
What about compounded semaglutide and tirzepatide?
Compounded versions of these ingredients are prepared by licensed compounding pharmacies. It is important to be precise about what that does and does not mean.
Compounded semaglutide and compounded tirzepatide arenot FDA-approved products.The clinical trial data described throughout this article — SURMOUNT-5, SURMOUNT-1, STEP 1 — was generated using the branded, FDA-approved formulations. Compounded preparations have not been through that evaluation, and results from those trials cannot be assumed to transfer.
If you are considering a compounded option, the questions worth asking any provider are: which pharmacy prepares it, is that pharmacy state-licensed and in good standing, is third-party purity and potency testing available, and is a physician supervising your dosing and monitoring. A clinic unwilling to answer those questions directly is the wrong clinic.
How we evaluate this at Prime Body Solutions in Liberty Lake and Spokane
We treat the choice between semaglutide and tirzepatide as a clinical decision, not a menu selection. That means baseline lab work before anything is prescribed, including metabolic panel, A1c, lipids, thyroid function, and hormone markers where indicated.
Hormones matter more here than most weight loss programs acknowledge. Low testosterone in men and thyroid dysfunction in either sex will blunt results from a GLP-1 medication, and treating one without assessing the other leaves outcomes on the table. Patients across the Spokane area — Spokane Valley, Liberty Lake, Post Falls, Coeur d'Alene, and Hayden — frequently arrive having tried a weight loss program that never checked a hormone panel.
We titrate deliberately rather than aggressively, track body composition rather than scale weight alone, and set protein and resistance training targets alongside the prescription. Dr. Belkoff supervises every treatment plan. Our clinic holds LegitScript certification, an independent verification standard for providers dispensing these medications.
Frequently asked questions
Is tirzepatide stronger than semaglutide?
Yes, for weight loss. SURMOUNT-5 found 20.2% mean weight reduction with tirzepatide versus 13.7% with semaglutide over 72 weeks. Tirzepatide activates two hormone pathways rather than one.
How long does it take to see results?
Appetite changes are often noticeable within the first few weeks. Meaningful weight loss accumulates over months. In SURMOUNT-5, maximum effect appeared at the highest tolerated doses at around 72 weeks, roughly 1.4 years of treatment.
Can I switch from semaglutide to tirzepatide?
Switching is common and clinically reasonable, particularly when weight loss has plateaued or side effects are limiting. It should be done under physician supervision with a fresh titration schedule rather than a direct dose swap.
Will I regain the weight if I stop?
Partial regain after discontinuation is well documented for both medications. Obesity behaves as a chronic condition, and these drugs treat it rather than cure it. Long-term planning should be part of the conversation before starting, not after.
Do these medications cause muscle loss?
Any rapid weight loss reduces lean mass along with fat. The countermeasures are adequate protein intake, resistance training, and tracking body composition rather than scale weight alone.
Where can I get semaglutide or tirzepatide near Spokane?
Prime Body Solutions provides physician-supervised medical weight loss from locations in Liberty Lake and Spokane, Washington, serving patients throughout Spokane Valley, Post Falls, Coeur d'Alene, and Hayden.
Sources
Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5).N Engl J Med. 2025.doi:10.1056/NEJMoa2416394
American College of Cardiology. SURMOUNT-5: Greater Loss of Weight, Waist Circumference With Tirzepatide Than Semaglutide.acc.org
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1).N Engl J Med. 2022.doi:10.1056/NEJMoa2206038
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).N Engl J Med. 2021;384(11):989-1002.PMID: 33567185
Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1, 3-year).N Engl J Med. 2025;392(10):958-971.PMID: 39536238
Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of SURMOUNT-5.PMC12448458
Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study.PMC12924827
This article is for educational purposes and is not medical advice. Semaglutide and tirzepatide are prescription medications with significant risks and contraindications, including a boxed warning regarding thyroid C-cell tumors. Decisions about treatment belong with a licensed clinician who knows your medical history. Compounded formulations are not FDA-approved. Reviewed by Cody Belkoff, DO, on August 31, 2026.
